Clinical Trial Update: Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating carboplatin/BBBD with the addition of Rituxan for recurrent primary CNS lymphoma (PCNSL) was terminated; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Lymphoma

Drugs mentioned

• Carboplatin/BBBD
• Rituxan (rituximab)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ | Phase 2 | Status: TERMINATED | Results posted: 2011-11-16